Thrombin activatable fibrinolysis inhibitor activity, thrombin-antithrombin complex and D-dimer levels in preterm neonates with early respiratory distress syndrome

American Journal of Hematology

Volumn 83, Issue 1, 2008, Pages 50-53

  Gursoy, Tugba ^a   Tekinalp, Gulsevin ^a   Yurdakok, Murat ^a   Ozcebe, Osman ^a   Korkmaz, Ayse ^a   Gurgey, Aytemiz ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX;

APGAR SCORE; ARTICLE; ASPHYXIA; BLOOD PH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FIBRINOLYSIS; HUMAN; MALE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; PREMATURITY; PRIORITY JOURNAL; THROMBOCYTE COUNT; UMBILICAL CORD BLOOD;

ANTITHROMBINS; CARBOXYPEPTIDASE U; DIMERIZATION; ENZYME ACTIVATION; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; INFANT, NEWBORN; MALE; PLATELET COUNT; RESPIRATORY DISTRESS SYNDROME, NEWBORN; THROMBIN; TIME FACTORS;

EID: 38349054795     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21010     Document Type: Article

References (31)

1. Hasegawa N, Husari AW. Role of the coagulation system in ARDS. Chest 1994;105:268-277.
2. Brus F, Van Oeveren W, Okken A, Oetomo SB. Activation of the plasma clotting, fibrinolytic, and kinin-kallikrein system in preterm infants with severe idiopathic respiratory distress syndrome. Pediatr Res 1994;36:647-653.
3. Stark CR, Abramson D, Erkan V. Intravascular coagulation and hyaline membrane disease of the newborn. Lancet 1968;2:1180-1181.
4. Brus F, Van Oeveren W, Okken A, Oetomo SB. Disease severity correlated with plasma clotting, fibrinolytic, and kinin-kallikrein system in preterm infants with respiratory distress syndrome. Pediatr Res 1997;41:120-127.
5. Brus F, Oetomo SB, Schieving J, et al. Increased tissue-type plasminogen activator is not accompanied by increased systemic fibrinolytic activity in severe neonatal respiratory distress syndrome. Pediatr Res 1999;45:588-594.
6. Yurdakök M, Oran O, Dündar S, et al. Reduced fibrinolytic state in early respiratory distress syndrome. Am J Hematol 1993;42:233-234.
7. Yurdakök M, Yiǧit Ş, Gürakan B, et al. Thrombin antithrombin III and prothrombin fragment 1.2 levels in early respiratory distress syndrome. Am J Hematol 1996;51:247-248.
8. Yurdakök M, Yiǧit S, Aliefendioǧlu D, et al. Plasma thrombomodulin levels in early respiratory distress syndrome. Turk J Pediatr 1998;40:85-88.
9. Yurdakök M, Korkmaz A, Kirazli Ş, et al. Global fibrinolytic capacity in early respiratory distress syndrome: A pilot study. Am J Hematol 2002;69:255-257.
10. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003;1:1566-1574.
11. Deguchi K, Noguchi M, Yuwasaki E, et al. Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). Am J Hematol 1991;38:86-89.
12. Kolde H-J., ed. Fibrinolysis. Haemostasis: Physiology, Pathology, Diagnostics. Basel: Pentapharm Ltd; 2001. pp 45-51.
13. Hori Y, Gabazza EC, Yano Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:660-665.
14. Yurdakök M, Yiǧit S, Gürakan B, et al. Plasma plasminogen levels in early respiratory distress syndrome. Turk J Pediatr 1996;38:195-197.
15. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-172.
16. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-1657.
17. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990;12:95-104.
18. Albisetti M. The fibrinolytic system in children. Semin Thromb Hemost 2003;29:339-347.
19. Petaja J, Manco-Johnson MJ. Protein C pathway in infants and children. Semin Thromb Hemost 2003;29:349-361.
20. Chalmers EA. Neonatal coagulation problems. Arch Dis Child Fetal Neonatal Ed 2004;89:F475-F478.
21. Andrew M, Broker L, Leaker M, et al. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost 1992;68:325-330.
22. Kolde H-J. Tests for haemostasis activation. Haemostasis: Physiology, Pathology, Diagnostics. Basel: Pentapharm Ltd; 2001. pp 119-127.
23. Knofler R, Hofmann S, Weissbach G, et al. Molecular markers of the endothelium, the coagulation and the fibrinolytic systems in healthy newborns. Semin Thromb Hemost 1998;24:453-461.
24. Dati F, Pelzer H, Wagner C. Relevance of markers of hemostasis activation in obstetrics/gynecology and pediatrics. Semin Thromb Hemost 1998;24:443-448.
25. Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human acute lung injury - New therapeutic targets? Keio J Med 2005;54:142-149.
26. Smith AA, Jacobson LJ, Miller BI, et al. A new euglobulln clot lysis assay for global fibrinolysis. Thromb Res 2003;112:329-337.
27. Uszynski W, Zekanowska E, Szymanski W, Uszynski M. Concentration of thrombin activatable fibrinolysis inhibitor (TAFI) in cord blood and maternal blood during labor. Ginekol Pol 2003;74:1329-1334.
28. Kuhle S, Male C, Mitchell L. Developmental hemostasis: Pro- and anticoagulant systems during childhood. Semin Thromb Hemost 2003;29:329-338.
29. Pinsky DJ, Liao H, Lawson CA, et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 1998;102:919-928.
30. Mosnier LO, Buijtenhuijs P, Marx PF, et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003;101:4844-4846.
31. Salonvaara M, Riikonen P, Kekomaki R, et al. Effects of gestational age and prenatal and perinatal events on the coagulation status in premature infants. Arch Dis Child Fetal Neonatal Ed 2003;88:F319-F323.